Skip to main content

Table 6 Estimated cost-effectiveness of the different strategies

From: Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

Strategy

QALY

Cost ($)

ICER ($/QALY)

no vaccination

22.427

3 348.8

reference

vaccination

22.437

3 629.2

27 588

  1. QALY: quality-adjusted life years, ICER: incremental cost-effectiveness ratio.
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us